Glaukos (NYSE:GKOS) Director Gilbert Kliman Sells 5,000 Shares

Glaukos Corporation (NYSE:GKOS) Director Gilbert Kliman sold 5,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $135.00, for a total transaction of $675,000.00. Following the sale, the director owned 35,528 shares of the company’s stock, valued at approximately $4,796,280. The trade was a 12.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Glaukos Stock Performance

GKOS stock traded up $0.83 during trading on Wednesday, hitting $137.19. 490,221 shares of the company’s stock traded hands, compared to its average volume of 792,839. The company has a quick ratio of 4.73, a current ratio of 5.43 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $146.75. The stock has a fifty day moving average price of $116.05 and a two-hundred day moving average price of $110.69. The stock has a market capitalization of $8.06 billion, a price-to-earnings ratio of -41.83 and a beta of 0.94.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The firm had revenue of $150.57 million during the quarter, compared to analyst estimates of $137.00 million. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. The firm’s revenue for the quarter was up 41.2% compared to the same quarter last year. As a group, equities analysts anticipate that Glaukos Corporation will post -0.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Glaukos

A number of institutional investors and hedge funds have recently modified their holdings of the stock. First Trust Advisors LP lifted its position in shares of Glaukos by 2,085.8% during the 1st quarter. First Trust Advisors LP now owns 42,754 shares of the medical instruments supplier’s stock valued at $4,603,000 after acquiring an additional 40,798 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Glaukos by 5.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 34,256 shares of the medical instruments supplier’s stock valued at $3,688,000 after acquiring an additional 1,786 shares during the last quarter. Summit Global Investments lifted its position in shares of Glaukos by 25.5% during the 1st quarter. Summit Global Investments now owns 8,849 shares of the medical instruments supplier’s stock valued at $953,000 after acquiring an additional 1,797 shares during the last quarter. Parallel Advisors LLC lifted its stake in Glaukos by 159.2% during the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 226 shares in the last quarter. Finally, Swiss National Bank lifted its stake in Glaukos by 0.4% during the first quarter. Swiss National Bank now owns 113,600 shares of the medical instruments supplier’s stock valued at $12,230,000 after buying an additional 500 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a research report on Friday, January 30th. BTIG Research upped their price target on shares of Glaukos from $131.00 to $141.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Citigroup upped their price target on shares of Glaukos from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a research report on Tuesday, April 21st. Finally, JPMorgan Chase & Co. upped their price target on shares of Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $144.42.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.